Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Zydus is the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidaemia.
The group’s origin can be traced to 1952 when it was founded by Late Mr Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr Pankaj R. Patel, the Chairman and Managing Director of the group. The group aims to be a leading healthcare provider with a robust product pipeline and aspires to be a research based pharmaceutical company by 2020.
The Zydus group was one amongst the top five companies worldwide at the FT ArcelorMittal Boldness in Business Awards 2014 in the Developing Markets category and was declared as the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010. In January 2014, Mr Pankaj Patel was conferred the India Innovator Award 2013 at the India Business Leaders Awards instituted by CNBC
Zydus has a strong presence in the markets of India, US, Europe (France & Spain), high profile markets of Latin America, South Africa and other emerging markets worldwide.